Kate M. Growley
Overview
Businesses around the globe rely on Kate M. Growley to navigate their most challenging digital issues, particularly those involving cybersecurity, artificial intelligence, digital infrastructure, and their intersection with national security. Clients seek her guidance on proactive compliance, incident response, internal and government-facing investigations, and policy engagement. With a unique combination of legal, policy, and consulting experience, Kate excels in translating complex technical topics into advice that is practical and informed by risk and business needs. | ![]() |
Career & Education
- Florida State University, B.S., summa cum laude, International Relations
- University of Virginia School of Law, J.D.
- Virginia
- District of Columbia
Kate's Insights
Client Alert | 3 min read | 08.26.25
On July 31, 2025, the Department of Justice (DOJ) announced that Illumina, Inc. will pay $9.8 million to resolve allegations that it violated the False Claims Act (FCA) by selling genomic sequencing systems with software containing cybersecurity vulnerabilities to federal agencies. This is the first FCA settlement involving claims that a medical manufacturer failed to incorporate adequate product cybersecurity into its software design and development.The allegations were first made in United States ex rel. Lenore v. Illumina Inc., No. 1:23-cv-00372 (D.R.I.), a qui tam action filed by Illumina’s former Director for Platform Management, On-Market Portfolio in September 2023. The relator alleged that, between February 2016 and September 2023, Illumina knowingly sold genomic sequencing systems to government agencies without adequate security programs or quality systems to identify and address software vulnerabilities. The complaint further alleged that Illumina failed to properly resource personnel and processes responsible for product security, did not remediate design features introducing cybersecurity risks, and misrepresented the software’s adherence to required cybersecurity standards.According to the government, Illumina’s actions included:
Press Coverage | 07.11.25
Client Alert | 4 min read | 07.07.25
DOJ Data Security Program Update: Active Enforcement Begins This Week
Insights
- |
08.01.25
Journal of Federal Agency Action
Global Developments: New Actions in the Asia-Pacific
|05.14.24
Privacy and Cybersecurity Outlook: The 2024 Landscape
China: Recent Developments In Cross-Border Data Transfer Requirements
|12.18.23
OneTrust DataGuidance
Cybersecurity Provisions Proliferate In The National Defense Authorization Act
|03.15.22
Government Contracting Law Report
Advancing America’s Dominance in AI: The 2021 National Defense Authorization Act’s AI Developments
|05.06.21
The Journal of Robotics, Artificial Intelligence & Law
- |
04.27.21
Government Contracting Law Report
"Approaching Privacy in Ethical AI: The Pros, Cons and Grays," IAPP Asia Privacy Forum 2023, Singapore.
|07.20.23
Pentagon To Require New Cybersecurity 'Certification' From Defense Contractors
|05.31.19
Inside Defense
Last Chance to Comment on FASC Rule – More Supply Chain Restrictions Coming
|10.27.20
Crowell & Moring’s Government Contracts Legal Forum
Chinese Individual Indicted for Alleged Trade Secret Theft from Semiconductor Company
|10.23.20
Crowell & Moring’s Trade Secrets Trends
Companies Protecting Trade Secrets Should Consider Role of NIST’s Enhanced Security Requirements
|07.16.20
Crowell & Moring’s Trade Secrets Trends
DoD Acquisition Chief Looks Back at the Year that Was and Previews the Year to Come
|12.24.19
Crowell & Moring's Government Contracts Legal Forum
Privacy & Cybersecurity – New York Enacts the SHIELD Act
|08.20.19
Crowell & Moring's International Trade Law
The U.S. Announces Endorsement of OECD’s Principles for Responsible AI
|06.04.19
Crowell & Moring's Government Contracts Legal Forum
- |
02.21.19
Crowell & Moring's Government Contracts Legal Forum
Kate's Insights
Client Alert | 3 min read | 08.26.25
On July 31, 2025, the Department of Justice (DOJ) announced that Illumina, Inc. will pay $9.8 million to resolve allegations that it violated the False Claims Act (FCA) by selling genomic sequencing systems with software containing cybersecurity vulnerabilities to federal agencies. This is the first FCA settlement involving claims that a medical manufacturer failed to incorporate adequate product cybersecurity into its software design and development.The allegations were first made in United States ex rel. Lenore v. Illumina Inc., No. 1:23-cv-00372 (D.R.I.), a qui tam action filed by Illumina’s former Director for Platform Management, On-Market Portfolio in September 2023. The relator alleged that, between February 2016 and September 2023, Illumina knowingly sold genomic sequencing systems to government agencies without adequate security programs or quality systems to identify and address software vulnerabilities. The complaint further alleged that Illumina failed to properly resource personnel and processes responsible for product security, did not remediate design features introducing cybersecurity risks, and misrepresented the software’s adherence to required cybersecurity standards.According to the government, Illumina’s actions included:
Press Coverage | 07.11.25
Client Alert | 4 min read | 07.07.25
DOJ Data Security Program Update: Active Enforcement Begins This Week